Literature DB >> 10155330

Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.

F Antoñanzas1, R Garuz, J Rovira, F Antón, C Trinxet, E Navas, L Salleras.   

Abstract

Hepatitis B virus (HBV) infection is an important public health problem all over the world. Vaccination is one way to prevent it, and several strategies can be used depending on endemicity, the main pattern of HBV transmission and the demographic structure of the population. In this study, an economic comparison of 3 vaccination strategies (mass adolescent vaccination, mass infant vaccination and mass combined vaccination) was performed in Catalonia, Spain. Screening pregnant women for HBV infection in combination with these strategies was also evaluated. Epidemiological models to analyse patterns of HBV infection with and without vaccination and to calculate HBV-associated costs were designed. Comparison between strategies was done using cost-effectiveness analysis from the perspective of the healthcare system. Epidemiological model results indicate that implementation of HBV vaccination could prevent as many as 104,778 new acute infections, and avoid up to 5239 chronic infections, 2096 cases of cirrhosis and 419 cases of hepatocarcinoma over a 20-year period in Catalonia. Cost-effectiveness analysis shows that mass adolescent vaccination is the most efficient strategy, with lower costs per avoided case than the other 2 strategies. When any of these strategies is complemented by screening for HBV in pregnant women, the number of avoided cases is always higher and the cost per avoided case decreases or remains unchanged.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10155330     DOI: 10.2165/00019053-199507050-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  28 in total

1.  Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; D Shouval
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

2.  [How and who should be vaccinated against hepatitis B in Spain?].

Authors:  M Bruguera
Journal:  Med Clin (Barc)       Date:  1984-03-31       Impact factor: 1.725

Review 3.  Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine.

Authors:  F E André; A Safary
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

4.  Cost effectiveness of antenatal hepatitis B screening and vaccination of infants.

Authors:  I L Thomas
Journal:  Aust N Z J Obstet Gynaecol       Date:  1990-11       Impact factor: 2.100

5.  Hepatitis B infection in sub-Saharan Africa. The African Regional Study Group.

Authors:  C F Kiire
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

6.  Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.

Authors:  M Krahn; A S Detsky
Journal:  Med Decis Making       Date:  1993 Jan-Mar       Impact factor: 2.583

7.  Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; S Berger; D Shouval
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

8.  A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.

Authors:  B S Bloom; A L Hillman; A M Fendrick; J S Schwartz
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

Review 9.  Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization.

Authors:  J E Maynard; M A Kane; S C Hadler
Journal:  Rev Infect Dis       Date:  1989 May-Jun

10.  [Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela].

Authors:  R Fernández Barboza; D Rivero; B Echeverría; I V Machado
Journal:  Bol Oficina Sanit Panam       Date:  1991-07
View more
  5 in total

Review 1.  Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).

Authors:  Giuseppe La Torre; Alice Mannocci; Rosella Saulle; Vittoria Colamesta; Angela Meggiolaro; Daniele Mipatrini; Alessandra Sinopoli
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

Review 2.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  [Economic evaluation of various hepatitis B vaccination strategies in children and adolescents].

Authors:  T D Szucs; A Smala; K Berger; A Windorfer
Journal:  Med Klin (Munich)       Date:  1998-08-15

Review 4.  Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques.

Authors:  Claudia Geue; Olivia Wu; Yiqiao Xin; Robert Heggie; Sharon Hutchinson; Natasha K Martin; Elisabeth Fenwick; David Goldberg
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

5.  The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study.

Authors:  Mohsen Moghadami; Nazanin Dadashpour; Ali Mohammad Mokhtari; Mostafa Ebrahimi; Alireza Mirahmadizadeh
Journal:  Braz J Infect Dis       Date:  2019-11-01       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.